Peramivir (rapivab 200MG/20ML (10MG/ML INJ soln))
Ended Awarded Last action
- Contract number
- 75A50324F80012
- Awardee
-
Biocryst Pharmaceuticals Inc. UEI MGXADJ6SCLJ5
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $13,877,674
Award facts
- Opportunity
-
- Reusable Insulated Shipping Containers Solicitation · 75A50324Q00006 · Posted Jun 5, 2024
- Contract value 20% obligated
-
- $13,877,673.75 Current, with exercised options
- $69,388,368.75 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27703, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $13,877,674 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a delivery order to Biocryst Pharmaceuticals Inc. on September 30, 2024, for the supply of Peramivir (RAPIVAB 200mg/20mL injection solution). This firm fixed-price contract, valued at approximately $69.4 million, is not set-aside and represents performance through September 29, 2025. The award leverages Biocryst's established Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), enabling the government to procure this specialized antiviral medication for influenza treatment through streamlined federal acquisition mechanisms. Performance will occur at the company's manufacturing facility in Durham, North Carolina.
Biocryst Pharmaceuticals, a biotechnology firm headquartered in Durham, specializes in small molecule drugs for rare and complex medical conditions. The company maintains significant indefinite delivery vehicles with federal healthcare agencies, including a $10 million Blanket Purchase Agreement with the VA National Acquisition Center and a multiple-award Federal Supply Schedule contract, both facilitating expedited procurement of critical medications including Peramivir and Orladeyo. This delivery order reflects the company's established role as a key supplier of specialized pharmaceutical products to support federal healthcare operations, with no competitive set-aside restrictions applied to the award.
Quick answers
Who was awarded contract 75A50324F80012?
75A50324F80012 was awarded to Biocryst Pharmaceuticals Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2024.
How much is contract 75A50324F80012 worth?
The government has obligated $13,877,674 on 75A50324F80012. Its potential value, with all options, is $69,388,369.
Is contract 75A50324F80012 an order under another contract?
Yes. 75A50324F80012 is a delivery order under 36F79721D0166, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 75A50324F80012 competed?
The extent of competition for 75A50324F80012 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award